Fremanezumab-vfrm
Fremanezumab-vfrm
Fremanezumab-vfrm (pronunciation: free-man-ez-umab-vfrm) is a monoclonal antibody medication used for the prevention of migraine in adults. It is marketed under the brand name AJOVY by Teva Pharmaceuticals.
Etymology
The name Fremanezumab-vfrm is derived from the International Nonproprietary Names (INN) system. The "-mab" suffix indicates it is a monoclonal antibody, while "Fremanezumab" is a unique identifier.
Mechanism of Action
Fremanezumab-vfrm works by binding to the calcitonin gene-related peptide (CGRP) or its receptor. CGRP is a neuropeptide that plays a crucial role in the pathophysiology of migraines. By blocking CGRP, Fremanezumab-vfrm can prevent the onset of migraines.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Migraine: A type of headache characterized by recurrent attacks of moderate to severe pain, often on one side of the head, and accompanied by nausea, vomiting, and sensitivity to light and sound.
- Neuropeptide: A type of molecule involved in communication between neurons in the brain.
- CGRP: Calcitonin gene-related peptide, a molecule that plays a key role in the transmission of pain signals in the nervous system.
- Teva Pharmaceuticals: An international pharmaceutical company that specializes in the development, production, and marketing of generic and proprietary branded pharmaceuticals.
External links
- Medical encyclopedia article on Fremanezumab-vfrm
- Wikipedia's article - Fremanezumab-vfrm
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski